From 2019 to 2027, the global breast cancer liquid biopsy market is expected to grow at a CAGR of 19.23% from almost $88,000 thousand in 2019 to approximate $36000 thousand in 2027.
Blood is used as a sample in the breast cancer liquid biopsy, which is a non-invasive alternative to surgical tissue biopsy. To identify breast cancer, different indicators are employed including circulating tumour cells (CTC), exocytoses, and CTC-derived tumour DNA. Using the heterogeneity of tumour cells found in advanced stages of breast cancer, breast cancer liquid biopsy can help track the disease’s progress. In addition, the EGFR gene mutations detected by the breast cancer liquid biopsy test assist clinicians in making timely treatment decisions for their patients with breast cancer.
This market is expected to expand as a result of the increasing prevalence of breast cancer, as well as an increase in demand for non-invasive breast cancer therapy, as well as technological advancements in breast cancer liquid biopsy, as well as the availability of financing for liquid biopsy R&D. There has also been an increase in the number of women who are aware of the treatment options available to them in the event that they develop breast cancer, as well as a rise in the use of liquid biopsy tests, an increase in the number of women undergoing pre-screening programmes for the disease, and a rise in the demand for breast cancer liquid biopsy reagents due to the advantages of these tests over more traditional ones. Underdeveloped countries’ limited access to and lack of knowledge about liquid biopsy for breast cancer will most likely impede market expansion.
On January 30, 2020, the World Health Organization (WHO) designated the CbreOVID-19 outbreak an international public health emergency. Around 210 countries have been affected by COVID-19. COVID-19 has had a limited impact on breast cancer liquid biopsy manufacturers and distributors because of shutdowns in COVID-19 impacted nations and an increase in the number of healthcare professionals becoming ill in the wake of the COVID-19 pandemic, which has resulted in a shortage of supplies. Following the onslaught of Coronavirus, a new variant known as Omicron emerges, with a faster transmission rate than corona.
Research and Development of Breast Cancer Liquid Biopsy
The global market for breast cancer liquid biopsy is divided into product and service, circulating biomarker, application, and region segments. There are three main types of reagent kits in this market: instruments and services. This biomarker is broken down into circulating tumor cells, extracellular vesicles, and tumour DNA. Diagnostics, prognostics, and risk assessment are some subcategories. The market is broken down into North America, Europe, Asia-Pacific, and Latin America, and the Caribbean.
Adaptive Biotechnologies, NeoGenomics Laboratories, Guardant Health, Inc., RainDance Technologies, Inc., Biocept Inc., Qiagen N.V., Trovagene, Inc., and F. Hoffmann-La Roche Ltd. are a few of the prominent players in the industry.
Benefits that are most important
- With the help of this research, investors will be able to see which areas of the market are most promising for long-term growth.
- As a result, stakeholders can take advantage of the current market opportunities by using the quantitative analysis provided in this report.
- The available prospects are identified through an in-depth examination of four distinct geographic locations.
- To have a clear picture of the worldwide market’s competitive landscape, the profiles and growth strategies of the major competitors are thoroughly evaluated.
The global liquid biopsy market is predicted to grow at a CAGR of 20.8 percent from 2018 to 2028, driven by the rising incidence of cancer around the world. Cancer and non-cancerous disorders can now be diagnosed and treated using non-invasive methods thanks to advances in technology.
elio plasma complete, a new NGS kit solution, will be launched by Personal Genome Diagnostics Inc. in June 2021. Researchers can use the kit to aid in areas such as treatment selection, biomarker discovery/monitoring, and genetic mutation analysis in a variety of cancer types. There is no need for invasive biopsy or tumour tissue collection using this method.
Low sensitivity and specificity are the main drawbacks of this approach.
Because of the tiny levels of circulating genetic material, liquid biopsy providers have worries about the procedure’s sensitivity. Additionally, results may reveal false positives, resulting in unnecessary treatment for patients. Because liquid biopsy results lack the desired specificity and sensitivity, physicians and researchers must rely on tissue biopsies instead. This is limiting the expansion of the market to some extent.
Read More Medical Post: Medical Imaging Workstations Market – Global Industry Research Analysis 2028